Investor’s Alert: Taylor Morrison Home Corporation (NYSE:TMHC) & Navidea Biopharmaceuticals, Inc. (NYSE:NAVB)

6

Taylor Morrison Home Corporation (NYSE:TMHC)

Taylor Morrison Home Corporation is a homebuilder and land developer engaged in building single-family detached and attached homes for first-time buyers, move-up families to luxury and active adult customers. The company operates under the Taylor Morrison brand, Monarch brand and Darling Homes brand. It operates in Arizona, California, Colorado, Florida and Texas. Taylor Morrison Home Corporation is headquartered in Scottsdale, Arizona.

Taylor Morrison Home Corporation (NYSE:TMHC)’s Financial Overview

Taylor Morrison Home Corporation (NYSE) surged 4.77% yesterday to close its trading session at $19.76. The company has 1 year Price Target of $19.56. Taylor Morrison Home Corporation has 52-Week high of $24.76 and 52-Week Low of $14.73. The stock touched its 52-Week High on 24.76 and 52-Week Low on 14.73. The stock traded with the volume of 1.36 Million shares yesterday. The firm shows the market capitalization of $2.39 Billion.

Taylor Morrison Home Corporation (NYSE) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.83/share against the analyst consensus estimate of $0.64/share. The difference between the actual and expected EPS is $0.19 a share with a surprise factor of 29.7%.

The firm is trading with SMA20 of 7.69 Percent, SMA50 of 13.45 Percent and SMA200 of 4.12 percent. Taylor Morrison Home Corporation has P/S value of 0.59 while its P/B value stands at 0.94. Similarly, the company has Return on Assets of 5.7 percent, Return on Equity of 11.6 percent and Return on Investment of 3.7 Percent. The company shows Gross Margin and Operating Margin of 19.1 percent and 7.3 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 2.8 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 9 analysts offering 12-month price forecasts for Taylor Morrison Home Corp have a median target of 19.00, with a high estimate of 25.00 and a low estimate of 16.00. The median estimate represents a -3.85% decrease from the last price of 19.76.

Taylor Morrison Home Corporation is expected* to report earnings on 02/13/2019 before market open. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 5 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.46. The reported EPS for the same quarter last year was $0.77.

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB)

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents for diseases such as cancer and Alzheimer. The Company’s radiopharmaceutical development programs include: Lymphoseek(R) & AZD4694 and RIGScan(TM). Navidea Biopharmaceuticals, Inc., formerly Neoprobe Corporation, is headquartered in Dublin, Ohio.

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB)’s Financial Outlook

The 1 analysts offering 12-month price forecasts for Navidea Biopharmaceuticals Inc have a median target of 2.40, with a high estimate of 2.40 and a low estimate of 2.40. The median estimate represents a +1,311.76% increase from the last price of 0.17.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

The Stock surged 6.25% and closed its last trading session at $0.17. The company has the market capitalization of $27.84 Million. The stock has 52-week high of $0.42 and 52-Week low of $0.1. The firm touched its 52-Week high on 0.42 and 52-Week low on 0.10. The company has volume of 395686 shares. The company has a total of 163.76 Million shares outstanding.

The company has YTD performance of 65.6 percent. Beta for Navidea Biopharmaceuticals, Inc. stands at 0.8 while its ATR (average true range) is 0.02. The company has Weekly Volatility of 13.07%% and Monthly Volatility of 12.02%%.

Navidea Biopharmaceuticals, Inc. has distance from 20-day Simple Moving Average (SMA20) of 20.3%, Distance from 50-Day Simple Moving Average of 20.52 percent and Distance from 200-Day Simple Moving Average of -14.67%.

The Company currently has ROA (Return on Assets) of -119.6 percent, Return on Equity (ROE) of -355.9 Percent and Return on Investment (ROI) of -101.6% with Gross margin of 94.6 percent and Operating & Profit margin of 0% and 0% respectively.

SHARE